Diabetes mellitus (DM) and heart failure (HF) are comorbid conditions associated with significant
morbidity and mortality worldwide. Despite the availability of novel and effective therapeutic options and intensive
glycaemic control strategies, mortality and hospitalisation rates continue to remain high and the incidence
of HF persists. In this review, we described the impact of currently available glucose-lowering therapies
in DM with a focus on HF clinical outcomes. Non-conventional modes of management and alternative pathophysiological
mechanisms with the potential for therapeutic targeting are also discussed.
Keywords: Heart failure, diabetes, T2DM, diabetic cardiomyopathy, HF, DM.
Rights & PermissionsPrintExport